Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Co. has developed its Targeted Alpha Therapies, or TAT, platform together with its proprietary Fast-Clear linker technology to enable them to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Co. serves health care sectors in Canada. The FUSN stock yearly return is shown above.
The yearly return on the FUSN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FUSN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|